Drug profile · INN
eltrombopag olamine
REVOLADE INITIAL APPROVAL
eltrombopag olamine (REVOLADE INITIAL APPROVAL) is a thrombopoietin receptor agonist. Associated with Amneal Pharma Europe Ltd. Route of administration: oral. Current US regulatory status: approved.
Drug details — eltrombopag olamine
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.89
Quick answer
eltrombopag olamine (REVOLADE INITIAL APPROVAL) is a thrombopoietin receptor agonist. Associated with Amneal Pharma Europe Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Thrombopoietin receptor agonist
Primary target: Thrombopoietin receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| PMDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is eltrombopag olamine?
eltrombopag olamine (REVOLADE INITIAL APPROVAL) is a thrombopoietin receptor agonist. Associated with Amneal Pharma Europe Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for eltrombopag olamine?
REVOLADE INITIAL APPROVAL is a marketed brand name for eltrombopag olamine. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of eltrombopag olamine?
eltrombopag olamine has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.